Last updated: July 18, 2026
AbbVie v. Sun Pharma 1:24-cv-00153: Litigation Summary, Claims at Issue, and Patent-Risk Implications
AbbVie Inc. v. Sun Pharmaceutical Industries Limited (case no. 1:24-cv-00153) is pending in the US District Court for the District of Delaware. The matter involves AbbVie’s asserted patent rights against Sun’s efforts to market a competing version of an AbbVie product through the Hatch-Waxman pathway. The immediate business impact is timing and market-entry leverage for any generic or follow-on launch tied to the asserted patents, with potential downstream exposure for formulary access, price erosion, and licensing leverage.
No litigation summary can be produced without the complaint’s asserted patent numbers, the specific Orange Book NDA(s)/ANDA(s), the counts (e.g., 35 U.S.C. § 271(e)(2)), the parties’ positions (infringement/invalidity contentions), and the docket’s procedural milestones (Answer, Motion to Dismiss, Claim Construction, Markman, scheduling order, preliminary injunction requests, and any settlements). With those items absent, any attempt to provide a “claims at issue” or “analysis” would be incomplete.
What are the asserted patents in AbbVie v. Sun Pharma 1:24-cv-00153?
A litigation-level patent-risk analysis requires the specific asserted US patents named in the complaint and the Orange Book linkage (NDA/ANDA). This case identifier alone is not sufficient to determine the asserted patent list, the asserted claims, or the claim construction schedule.
Which patents are listed as infringed under 35 U.S.C. § 271(e)(2)?
A complete summary depends on the asserted patent numbers and the counts tied to each patent. Without the complaint’s patent paragraph(s) and asserted claim numbers, the infringement allegations cannot be summarized.
What product linkage (NDA/ANDA) is in dispute?
Hatch-Waxman cases typically map asserted patents to an Orange Book listing. Without the ANDA or NDA number(s) referenced in the complaint, the specific drug and formulation strength cannot be tied to the alleged infringement.
What claims does Sun Pharma deny or challenge in AbbVie v. Sun Pharma 1:24-cv-00153?
A validity and non-infringement analysis requires the defenses raised in the Answer and any early motions (e.g., dismissal, indefiniteness, failure to state a claim). Without docket text, proposed invalidity theories, and the asserted technology differences, a defensible analysis cannot be provided.
What invalidity theories are likely argued (anticipation/obviousness/§ 101/indefiniteness)?
Invalidity analysis must be grounded in the specific arguments made, including cited references and claim constructions. Without those details, listing generic theories would not be a litigation summary.
What non-infringement position is taken (process, formulation, dosage form, exclusivity carve-outs)?
Non-infringement must be tied to the accused product description and Sun’s Paragraph IV certifications. Without the certification and product comparison, infringement-contentions cannot be summarized.
When did the case enter procedural milestones in AbbVie v. Sun Pharma 1:24-cv-00153?
A litigation timeline for business decisions needs: complaint filing date, service, Answer deadline and filing, scheduling order dates, Markman/claim construction dates, dispositive-motion deadlines, and trial date (or stay status).
Has the case been stayed pending PTAB or reexamination?
PTAB timing often determines whether business exposure should track claim scope changes. Without docket evidence, stay status cannot be stated.
Is there a claim construction or summary judgment posture?
A meaningful analysis requires knowing whether the court has issued a Markman order or ruled on dispositive motions.
Does AbbVie seek injunctive relief in AbbVie v. Sun Pharma 1:24-cv-00153?
Permanent injunction and automatic stay logic depends on: (i) whether this is a Paragraph IV ANDA litigation, (ii) whether an injunction was sought, (iii) court decisions on preliminary injunction, and (iv) whether the case involves a first generic filing.
Without docket entries describing remedies sought or any preliminary injunction motion, injunctive posture cannot be summarized.
What is the Orange Book status of the AbbVie product tied to 1:24-cv-00153?
Orange Book status requires the NDA number, listed patents, listed expiration dates, and any “delisted” timelines.
Without the Orange Book listing(s) referenced in the complaint, exclusivity, listed-patent lifetimes, and delisting history cannot be mapped.
When does exclusivity or patent protection end for the asserted AbbVie product in this case?
Exclusivity and patent-expiration mapping requires:
- NDA/Orange Book ID(s)
- each asserted patent’s expiration date and any terminal disclaimer
- pediatric exclusivity, extension terms, and regulatory exclusivities
Those inputs are not available from the case caption alone.
How strong is AbbVie’s patent estate in 1:24-cv-00153?
“Strength” in litigation context is anchored in:
- asserted claim breadth
- prosecution history relevant to scope
- whether asserted patents are near expiration or central to core formulation/process claims
- whether the patents have survived reexamination or PTAB review
- prior litigation outcomes for the same patents
Without the specific asserted patents and case filings, no defensible strength assessment can be produced.
What generic entry risks exist for Sun Pharma if AbbVie loses in 1:24-cv-00153?
Entry-risk modeling requires:
- which patents control the carve-out (stay) or trigger launch-blocking
- whether any settlement agreement is entered
- remaining exclusivity and non-asserted patent coverage
- whether an injunction would issue or be stayed pending appeal
No settlement or launch-readiness facts can be stated without docket and settlement record.
What patent litigation precedents affect AbbVie v. Sun Pharma 1:24-cv-00153?
Litigation impact depends on prior outcomes involving the same patents and the same technology. That requires identifying:
- which patent numbers are in suit
- whether those patents were litigated previously
- the claim construction that may bind later cases
Without the asserted patent list, prior-case mapping cannot be done.
Key Takeaways
- AbbVie Inc. v. Sun Pharmaceutical Industries Limited, 1:24-cv-00153, is pending in the District of Delaware, but a litigation summary cannot be accurately completed without the complaint and docket facts that identify the asserted patents, accused product linkage, procedural posture, and any settlement or injunction requests.
- Business impact analysis (entry timing, injunction risk, and patent-expiration exposure) depends on the asserted patent numbers and Orange Book linkage, which are not provided in the case identifier alone.
FAQs
- What patents are typically asserted in Hatch-Waxman cases like AbbVie v. Sun?
- How does an ANDA Paragraph IV certification affect the timing of launch against AbbVie?
- What court procedural steps determine claim scope in pharmaceutical patent suits?
- When do PTAB challenges change the settlement leverage in patent infringement cases?
- How are Orange Book “listed patents” used to quantify remaining entry risk for generics?
References
No sources were cited because no docket, complaint, Orange Book listing, or asserted patent identifiers were provided in the prompt.
